Business Description
Solventum Corp
NAICS : 339114
SIC : 3842
ISIN : US83444M1018
Total Employee Number:
20,000Compare
Compare
Traded in other countries / regions
SOLV.USAKB7.GermanySOLV.Mexico1SOLV.Italy Index Membership
S&P 500Russell 1000Russell 3000MSCI World Index IPO Date
2024-03-26Description
In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and wound prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.08 | |||||
Equity-to-Asset | 0.34 | |||||
Debt-to-Equity | 1.1 | |||||
Debt-to-EBITDA | 2.14 | |||||
Interest Coverage | 1.97 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.18 | |||||
Beneish M-Score | -2.4 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.3 | |||||
3-Year EBITDA Growth Rate | 3.4 | |||||
3-Year EPS without NRI Growth Rate | -7.7 | |||||
3-Year Book Growth Rate | -24.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.32 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 2.17 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.17 | |||||
9-Day RSI | 39.42 | |||||
14-Day RSI | 46.29 | |||||
3-1 Month Momentum % | 16.44 | |||||
6-1 Month Momentum % | 26.43 | |||||
12-1 Month Momentum % | 17.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.02 | |||||
Quick Ratio | 0.74 | |||||
Cash Ratio | 0.11 | |||||
Days Inventory | 100.91 | |||||
Days Sales Outstanding | 48.21 | |||||
Days Payable | 65.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.2 | |||||
Shareholder Yield % | 21.02 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 54.68 | |||||
Operating Margin % | 6.32 | |||||
Net Margin % | 17.26 | |||||
EBITDA Margin % | 29.7 | |||||
FCF Margin % | -1.42 | |||||
OCF Margin % | 2.52 | |||||
ROE % | 30.58 | |||||
ROA % | 10 | |||||
ROIC % | 3.63 | |||||
3-Year ROIIC % | 76.43 | |||||
ROC (Joel Greenblatt) % | 129.49 | |||||
ROCE % | 17.52 | |||||
Years of Profitability over Past 10-Year | 6 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 10.7 | |||||
Forward PE Ratio | 12.07 | |||||
PE Ratio without NRI | 9.46 | |||||
PS Ratio | 1.83 | |||||
PB Ratio | 3.1 | |||||
Price-to-Operating-Cash-Flow | 72.61 | |||||
EV-to-EBIT | 10.08 | |||||
EV-to-Forward-EBIT | 26.5 | |||||
EV-to-EBITDA | 8.1 | |||||
EV-to-Forward-EBITDA | 15.28 | |||||
EV-to-Revenue | 2.38 | |||||
EV-to-Forward-Revenue | 2.39 | |||||
EV-to-FCF | -167.65 | |||||
Earnings Yield (Greenblatt) % | 9.92 | |||||
FCF Yield % | -0.79 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:SOLV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Solventum Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 8,310 | ||
| EPS (TTM) ($) | 8.181 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 33.67 | ||
| 14-Day RSI | 46.29 | ||
| 14-Day ATR ($) | 2.340972 | ||
| 20-Day SMA ($) | 90.207 | ||
| 12-1 Month Momentum % | 17.21 | ||
| 52-Week Range ($) | 62.38 - 94.16 | ||
| Shares Outstanding (Mil) | 170.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Solventum Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Solventum Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 16:30 | In 162 days | ||
| Annual report for 2026 | 2027-02-26 | In 161 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 161 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 50 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 49 days | ||
| Guidance call for 2026 | 2026-09-09 10:15 | 90.11 (-0.69%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | 87.94 (-0.07%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 87.94 (-0.07%) | ||
| Guidance call for 2026 | 2026-06-03 09:55 | 76.43 (+1.26%) | ||
| General meeting for 2026 | 2026-05-15 09:00 | 74.42 (+0.73%) |
Show
Entries
Solventum Corp Frequently Asked Questions
What is Solventum Corp(SOLV)'s stock price today?
The current price of SOLV is $87.53. The 52 week high of SOLV is $94.16 and 52 week low is $62.38.
When is next earnings date of Solventum Corp(SOLV)?
The next earnings date of Solventum Corp(SOLV) is 2026-11-06 Est..
Does Solventum Corp(SOLV) pay dividends? If so, how much?
Solventum Corp(SOLV) does not pay dividend.
Guru Commentaries on NYSE:SOLV
Pzena Focused Value Strategy
Bullish
2025 Q3
What the manager wrote
We initiated a new position in medical device company Solventum, a recent spinoff from 3M. Concerns around operational challenges and margin pressure caused by the separation from 3M, in addition to high financial leverage, resulted in an attractive entry point. We expect the company to benefit from self-help opportunities going forward as an independent company and see a clean balance sheet after recently divesting a non-core asset at a premium valuation.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers